The Company’s Annual General Meeting (“AGM”) will be held exclusively as an open online meeting at 1pm BST/2pm CEST on Thursday, 5 October 2023.

The AGM comprises both ordinary and extraordinary resolutions.

All materials can be found on our investors page.

Shareholders are strongly encouraged to submit their votes in advance, in accordance with the instructions in the Notice of the AGM.

Enabling informed clinical decision-making through quality diagnostics in the right place, at the right time.

Novacyt is a leading global diagnostics company. We protect people and society in the fight against infectious diseases by developing tests that accurately detect infections, allowing us to help safeguard people and public health. We pride ourselves on our ability to develop solutions that target high unmet needs in infectious diseases and our agility in responding to significant outbreaks around the world with diagnostic products and solutions.

We can do all this thanks, in part, to our intelligence-driven approach which guides our research, development and innovation, allowing us to remain ahead of the curve and at maximum preparedness for invisible threats both today and in the future.

We safeguard lives from invisible threats

Near-patient testing

Our solutions bring diagnostics closer to patients where they are needed most, supporting decentralised testing.

Scalable, fast, molecular diagnostics

Our PROmate® assays provide rapid results within 80 mins from swab to completed qPCR for multiple samples.

Agile & versatile

Using technical expertise to detect a broad range of pathogens; Respiratory, gastrointestinal, transplant and insect-borne.

Exceptional customer & technical services

Our services don’t stop at the products themselves. Our customer services and field application support teams are part of the Novacyt solution, ensuring you get maximum value from our products.

About

Find out more about our company

Products & Solutions

Explore our diagnostic solutions

Prepared

Novacyt strives to tackle high unmet needs in diagnostics with customer focused solutions. Our broad product portfolio and continual innovation enable us to remain prepared and ready to react quickly to new and changing customer needs and priorities. Our speed and agility also enable us to deliver critical products and solutions for significant outbreaks, as demonstrated in our response to the COVID-19 pandemic and prior outbreaks including Zika, H1N1 (swine flu) and Ebola.

COVID-19

We are committed to being first or fast in the global fight against infectious diseases and are proud to have provided the first CE-marked test for COVID-19, followed by additional COVID-19 solutions including our proprietary direct-to-pcr PROmate COVID-19 2G designed to detect two SARS-CoV-2 targets. We are a trusted provider of diagnostic tests to health systems, private providers and non-governmental organisations.

Intelligent Innovation

Our products are researched and developed using a customer insights and market-led approach. We use intelligence, data and analysis to track emerging threats to be in a position to offer exactly what healthcare professionals, governments, individuals and organisations need, when it’s needed most.

We are informed by our life sciences expertise, scientific relationships and global surveillance systems. Identifying trends means we can allocate resources ensuring we have reliable solutions to meet expected demand.

  • “Accuscience had a great journey over the past number of years with the Novacyt Group. Accuscience has been a key supplier to the Irish Government during the pandemic, and Novacyt’s SARS-CoV-2 kits have been key products used in Ireland in the fight against COVID-19. The partnership Accuscience has with the Novacyt’s Sales and Technical teams has been paramount in the success we have seen in the Irish COVID-19 testing market. In many cases, the team in Novacyt has gone over and above to help us support the Irish customer base."

    Niamh Foley
    Commercial Director @ Accuscience

  • “As soon as we started to see that there was a need for COVID-19 testing, we thought of Novacyt immediately. We wanted to collaborate as soon as we could as we have a long working relationship. Novacyt were very good, they had one of the first recognised products on the market which is the genesig® COVID-19 1G. First validation with the assay was good, and we didn’t see any problem. It is a nice assay that you can run a variety of different ways and it works on open platforms."

    Tony Cooke
    CEO @ Cambridge Clinical Labs

  • “We have a long-standing relationship with Novacyt, based on the excellent service and products they provide us. Their kits are vital to our pathogen reporting, and in a time-critical industry, Novacyt have never let us, or our clients down with their availability or quality. This is a testimony to each account manager and the customer service team’s hard work and understanding. The technical support is also always on hand for any other queries.”

    Glyn Reynolds
    Diagnostic Manager @ Microsearch Laboratories Ltd.

  • “Last year, we were heavily involved in COVID-19 testing particularly in the Oil & Gas industry. The problem that we faced in the early days was the 24 - 48 hours delay in getting the results back. If we can test and send people onto the helicopter an hour later, it makes a huge difference. We had spoken to a few different companies when we started off, and we discovered Novacyt’s genesig assays. Novacyt’s staff were extremely responsible and responsive to all the questions we were firing at them. We formed a good relationship and trust with the employees there. And when Novacyt launched PROmate®, it was an easy decision for us to make and continue that relationship.”

    Ken Park
    Clinical Director @ TAC Healthcare